Analysis: Lamictal highlights increased class action scrutiny in pharma cases

15 May 2020

Analysis: Lamictal highlights increased class action scrutiny in pharma cases

Gina Chiappetta, Michael Hamburger and Adam Acosta

The US Court of Appeals for the Third Circuit on 22 April vacated class certification in a lawsuit alleging that GlaxoSmithKline and Teva suppressed generic competition to Lamictal, an anticonvulsant used to treat epilepsy and bipolar disorder. White & Case partner Michael Hamburger, senior associate Adam Acosta and associate Gina Chiappetta analyse how the appellate court’s decision fits into a broader trend of courts clamping down on class certification in pharmaceutical cases.